Otonomy Hearing Loss Candidate Shows Clinical Benefit On Multiple Efficacy Endpoints

Otonomy Inc OTIC announced topline results from the Phase 2a clinical trial of OTO-413 in subjects with hearing loss.
The trial demonstrated that a single intratympanic injection of 0.3 mg OTO-413 provided clinically meaningful treatment benefit versus placebo across multiple speech-in-noise (SIN) hearing tests and the Patient Global Impression of Change at consecutive time points (Days 57 and 85).
40% (8 of 20) of OTO-413 subjects demonstrated a clinically meaningful improvement on at least one of the three SIN tests versus 20% (2 out of 10) for placebo.
Also See: Otonomy's OTO-825 Gene Therapy Can Restore Meaningful Hearing Function, Animal Study Shows.
15% (3 of 20) OTO-413 subjects demonstrated a clinically-meaningful improvement by two or more different SIN tests versus 0% (0 of 10) for placebo.
For the Words-in-Noise test, 40% (6 of 15 with evaluable tests) of OTO-413 subjects demonstrated a clinically meaningful improvement versus 0% (0 of 9 with evaluable tests) for placebo.
Treatment with OTO-413 was well tolerated. 32% of OTO-413 and 46% of placebo subjects reported an AE, most of which were mild.
Otonomy intends to initiate a full dose-ranging Phase 2 trial in hearing loss patients by the end of 2022, incorporating learnings from the ongoing higher dose evaluations assessing two higher doses of OTO-413: 0.75 mg and 1.50 mg.
Results from the higher dose evaluation are expected in 2H of 2022.
Price Action: OTIC shares are up 0.46% at $2.11 during the market session on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs

Otonomy Hearing Loss Candidate Shows Clinical Benefit On Multiple Efficacy Endpoints

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga